Tag: Teva schizophrenia therapy

news-24092024-140004

Monthly Schizophrenia Therapy: Teva’s Safety Profile Highlighted

Teva Pharmaceuticals recently shared new safety data from the Phase III SOLARIS trial and a Phase I study regarding extended-release subcutaneous olanzapine, TEV-‘749. This...